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 Editorial
Obesity, Lean Body Mass, and Sugammadex Dosing 
Recently, Merck issued a recommendation for sugammadex dosing for 
reversal of neuromuscular junction (NMJ) blockade.1 Appropriately, 
the guideline assumes assessment of residual block using some form 
of nerve stimulator to assess any residual block. Less appropriate is 
the recommendation that dosing is based simply on the weight of the 
patient. With obesity an increasing global health issue, the question 
of drug dosing by weight is an increasing conundrum.  Drug dosing 
is always an approximation. For the typically fast acting drugs that 
anesthesiologists employ, the key is to rapidly load the plasma and 
interstitial fluid volumes, so that drug binds in equilibrium with the 
plasma/interstitial volume concentration. The paper by Bougouma and 
Demeere2 attempts to achieve a rational approach to drug doing in the 
obese patients, specifically for sugammadex reversal of rocuronium.
Drug dosing based on body weight presumes that the volume of 
distribution is the plasma/interstitial volume and is some relatively 
fixed proportion of body weight (~20%). The typically recommended 
drug doses based on ideal body mass (IDM) are expected to provide a 
relatively certain concentration, also realizing that protein binding will 
influence the free drug concentration that interacts with the receptor.
But the increasingly world-wide epidemic of obesity changes drug 
dosing. Some argue that you should dose the real body weight. 
However, adipose tissue occupies a large volume but is poorly perfused, 
and obligates little cardiac output or blood volume. However, an excess 
of adipose tissue does obligate extra skin to cover it and extra muscle to 
carry it around, and these tissues increase blood and plasma volume and 
cardiac output. Thus obesity increases the volume of drug distribution, 
but not in proportion to weight.3,4 Using real body weight will result in 
giving an excess of drug since the volume of distribution is not increased 
in proportion to weight. But while some might argue to use ideal body 
weight, obese patients will have some increase in cardiac output, blood 
volume and interstitial fluid, so that dosing by ideal body weight will 
result in under-dosing obese patients. 
The suggestion has been made to calibrate drug dosing based on 
lean body mass (LBM) which increases with real body mass, but not in 
proportion to total body mass. LBM, for someone with normal body 
mass, is typically about 75-85% of what a person ‘should’ actually weigh, 
that is, ideal body mass (IBM); measured LBM typically identifies 15-25% 
body fat to be normal (higher in women than men). The benefit of using 
LBM, which includes muscle and skin, is that it will increase with obesity 
(increased skin to cover the fat and increased muscle to carry it around), 
but not in proportion to the total mass. The LBM is what obligates 
cardiac output and blood volume. Unfortunately, most recommended 
drug dosing uses real body mass (ignoring the obesity issue), therefore 
doses based on LBM will underdose patients. In the study in question, 
the drugs administered in mg/kg were appropriately increased.
But how is LBM calculated? A variety of measurements including total 
body potassium have been used. An often-used formula to calculate 
the value as in the present paper is that of James5 that appears to have 
been based on people of near normal body mass. If one extrapolates 
to weights approaching twice IBM, the calculated LBM (CLBM) declines; 
near 3.5x IBM the CLBM eventually goes to zero! Alternative formulae 
that avoid this problem are those of Hume6 and Boer4. Those formulae 
achieve a more accurate value, but are both are well below the IBM. 
Figure 1 below compares the various CLBM for a woman with an IBM of 
60 kg, height of 1.65 m (65 inches), as the real body mass (RBM) varies 
up to 130 kg and body mass index (BMI) increases from 22 to 46.3. The 
James calculation can be seen to actually decline above a BMI of 41.
An alternative value proposed by Lemmens et al.7,8 determines a lean 
scaling factor (LSF) to arrive at a lean scaled weight (LSW, using their 
terminology weight for mass). Lemmens formula uses body mass index 
(BMI) to appropriately modify the real body mass (RBM): 
 (LSW), female = RBM x LSF = RBM x 14,148/(8,780 + 244 x BMI). 
(LSW), male = RBM x LSF = RBM x 11,432/(6,680 x 216 x BMI).  
LSW provides a more accurate estimate of blood volume and interstitial 
volume (which is what we are loading with our drugs). The LSW is 
also plotted in Figure 1 and would appear to provide a reasonable 
estimate for drug dosing in the obese patient, a value between IBM and 
RBM, between ideal and real. But even with iPhones and calculators, 
attempting to use such formulas in a busy OR might be distracting and 
impractical, and the value is an approximation in any case. So perhaps 
a simpler approximation of weight (or mass) for mg/kg dosing might 
be to use the simple average of IBM and RBM, i.e. (RBM+IBM)/2. For the 
110 kg patient who should weigh 60 kg, use 85 kg. This is not an LBM 
or LSW calculation, but does give an easily calculated body weight for 
dosing that approximates the LSW quite nicely (see Figure 1). It would 
give a dose somewhat lower than that promulgated by the Merck 
recommendation, but would also depend on the weight base used to 
calculate the rocuronium dose. In addition, there is variability in obesity 
as well: some patients with clearly morbid central corpulence and 
limited function, versus the healthy and vigorous fat patient. Both have 
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the same height and weight but certainly different lean body masses to 
carry the extra weight.
But there are other considerations. Sugammadex dosing represents a 
unique situation. For most pharmaceuticals administered, a drug is 
given to compete with another agent at a specific binding site (e.g. beta-
adrenergic blockers), or a drug is given to induce an opposite action 
to counteract some effect. But sugammadex reversal of rocuronium 
blockade of the NMJ is unlike any other drug used by anesthesiologists 
since it involves the specific and very high affinity binding of one drug 
to another. In theory, because there is binding of a single rocuronium 
molecule by one sugammadex molecule, all one has to do is give the 
same number of molecules of sugammadex. Based on the molecular 
weights (rocuronium: 530 Da; sugammadex: 2178 Da), 4 mg of 
sugammadex is required to bind 1 mg of rocuronium (approximately 
1.1x1018 or about one quintillion molecules of each!). Sugammadex does 
bind other steroid molecules, but with far lower affinity. In the present 
study, dosing the rocuronium based on CLBM is perfectly appropriate, 
and it worked well to use the same CLBM dosing of sugammadex.
However, to calculate the dose of sugammadex required, one might 
instead use the given dose of rocuronium minus the amount estimated 
to have been metabolized. For example, if 50 mg of rocuronium is given, 
and half of the amount is presumed metabolized after 30 minutes, 
one might give 100 mg sugammadex to bind the 25 mg rocuronium 
presumed remaining. Based on the original dose of rocuronium 
(50 mg) it would represent a 2:1 ratio (mg). In the present study the 
authors actually ended up giving the 20 patients an average mg ratio 
of 1.42±0.24. Since reversal was complete, presumably even more than 
50% of the rocuronium was metabolized.  
A problem may arise when an excess of sugammadex is given. A high 
dose ratio, say 16:1 instead of 4:1, should mean a more rapid reversal 
since it markedly increases the likelihood of a sugammadex molecule 
‘bumping into’ (to use non-statistical term) a rocuronium molecule. 
But in addition to being far more expensive, an excess of sugammadex 
molecules might bind other steroids in the blood (e.g. steroid birth 
control agents, corticosteroids given for nausea or to prevent allergic 
responses).
Thankfully, the presence of sugammadex represents a superior 
alternative to neostigmine (or even edrophonium). Whereas if an excess 
of neostigmine is used, it has the potential to cause weakness, an excess 
of sugammadex is unlikely to have consequences in reversal of NMJ 
blockade. The paper by Bougouma and Demeere provides a useful 
reminder to be thoughtful and calculating in drug administration.
Carl Lynch III
Department of Anesthesiology, University of Virginia Health Sciences 
Center, Charlottesville, Virginia 22908-0710 USA
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